Profil
Kathy Dong is currently the President & Chief Executive Officer at Electra Therapeutics, Inc. and also serves as a Director at Neuron23, Inc. Previously, she worked as the Chief Operating Officer at Star Therapeutics, Inc. Dr. Dong holds an MBA and a doctorate from the University of New Mexico School of Medicine.
Postes actifs de Kathy Dong
| Sociétés | Poste | Début |
|---|---|---|
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that focuses on developing precision medicines for genetically defined neurological and immunological diseases | Directeur/Membre du Conseil | 14/06/2022 |
Electra Therapeutics, Inc.
Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures therapies for immunological diseases and cancer | Directeur Général | 11/12/2023 |
Anciens postes connus de Kathy Dong
| Sociétés | Poste | Fin |
|---|---|---|
Star Therapeutics, Inc.
Star Therapeutics, Inc. BiotechnologyHealth Technology Develops antibody therapies | Directeur des opérations | - |
Formation de Kathy Dong
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
University of New Mexico School of Medicine
University of New Mexico School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that focuses on developing precision medicines for genetically defined neurological and immunological diseases | Commercial Services |
Electra Therapeutics, Inc.
Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures therapies for immunological diseases and cancer | Health Technology |
Star Therapeutics, Inc.
Star Therapeutics, Inc. BiotechnologyHealth Technology Develops antibody therapies | Health Technology |
















